Photodynamic therapy gains FDA approval for superficial BCC - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Photodynamic therapy gains FDA approval for superficial BCC

  • By

  • Kathryn Wighton

  • September 15, 2026

  • 2 min

Share

Objective:

To report the FDA approval of aminolevulinic acid hydrochloride (Ameluz) for the treatment of superficial basal cell carcinoma (BCC) in combination with photodynamic therapy.

Approach:
  • FDA Approval: The FDA approved Ameluz topical gel, 10%, for adults with superficial BCC, expanding its indication from actinic keratosis.
  • Clinical Trial: A phase 3 trial with 187 adults assessed the efficacy of Ameluz in achieving clinical and histological complete response.
Key Findings:
  • 95 of 145 patients (66%) treated with Ameluz achieved the primary end point compared to 2 of 42 patients (5%) receiving placebo photodynamic therapy.
  • Histological clearance of the main target lesion occurred in 76% of patients treated with Ameluz compared with 19% receiving placebo photodynamic therapy.
  • Complete clinical clearance of all target lesions occurred in 83% of patients receiving Ameluz compared with 21% receiving placebo photodynamic therapy.
Interpretation:

Application-site reactions were the most frequently observed adverse reactions.

Limitations:
  • Thesudywalimocnrzbvg
Conclusion:

Ameluz represents a new treatment option for patients with superficial BCC.

Sources:

Original Source(s)

Related Content